4//SEC Filing
SVLSF V, LLC 4
Accession 0001104659-19-032917
CIK 0001761612other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 9:26 PM ET
Size
30.1 KB
Accession
0001104659-19-032917
Insider Transaction Report
Form 4
SVLSF V, LLC
10% Owner
Transactions
- Conversion
Ordinary Shares
2019-05-28+18,485→ 18,485 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Conversion
Ordinary Shares
2019-05-28+13,169→ 31,654 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Conversion
Ordinary Shares
2019-05-28+623,196→ 1,497,905 total(indirect: By SV Life Sciences Fund V, L.P.) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+377,732$5,288,248→ 1,875,637 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Series B1 Preferred Shares
2019-05-28−623,196→ 0 total(indirect: By SV Life Sciences Fund V, L.P.)→ Ordinary Shares (623,196 underlying) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+7,983$111,762→ 39,637 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Conversion
Series B1 Preferred Shares
2019-05-28−13,169→ 0 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.)→ Ordinary Shares (13,169 underlying) - Conversion
Series A Preferred Shares
2019-05-28−18,485→ 0 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.)→ Ordinary Shares (18,485 underlying) - Conversion
Ordinary Shares
2019-05-28+874,709→ 874,709 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Series A Preferred Shares
2019-05-28−874,709→ 0 total(indirect: By SV Life Sciences Fund V, L.P.)→ Ordinary Shares (874,709 underlying)
SV LIFE SCIENCES FUND V LP
10% Owner
Transactions
- Conversion
Ordinary Shares
2019-05-28+623,196→ 1,497,905 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Series A Preferred Shares
2019-05-28−874,709→ 0 total(indirect: By SV Life Sciences Fund V, L.P.)→ Ordinary Shares (874,709 underlying) - Conversion
Series B1 Preferred Shares
2019-05-28−623,196→ 0 total(indirect: By SV Life Sciences Fund V, L.P.)→ Ordinary Shares (623,196 underlying) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+377,732$5,288,248→ 1,875,637 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Ordinary Shares
2019-05-28+874,709→ 874,709 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Ordinary Shares
2019-05-28+13,169→ 31,654 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Conversion
Ordinary Shares
2019-05-28+18,485→ 18,485 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+7,983$111,762→ 39,637 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Conversion
Series A Preferred Shares
2019-05-28−18,485→ 0 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.)→ Ordinary Shares (18,485 underlying) - Conversion
Series B1 Preferred Shares
2019-05-28−13,169→ 0 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.)→ Ordinary Shares (13,169 underlying)
SV Life Sciences Fund V (GP), LP
10% Owner
Transactions
- Conversion
Ordinary Shares
2019-05-28+874,709→ 874,709 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Ordinary Shares
2019-05-28+623,196→ 1,497,905 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Ordinary Shares
2019-05-28+18,485→ 18,485 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Conversion
Ordinary Shares
2019-05-28+13,169→ 31,654 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+7,983$111,762→ 39,637 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Conversion
Series A Preferred Shares
2019-05-28−874,709→ 0 total(indirect: By SV Life Sciences Fund V, L.P.)→ Ordinary Shares (874,709 underlying) - Conversion
Series B1 Preferred Shares
2019-05-28−623,196→ 0 total(indirect: By SV Life Sciences Fund V, L.P.)→ Ordinary Shares (623,196 underlying) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+377,732$5,288,248→ 1,875,637 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Series A Preferred Shares
2019-05-28−18,485→ 0 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.)→ Ordinary Shares (18,485 underlying) - Conversion
Series B1 Preferred Shares
2019-05-28−13,169→ 0 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.)→ Ordinary Shares (13,169 underlying)
Transactions
- Conversion
Ordinary Shares
2019-05-28+874,709→ 874,709 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Ordinary Shares
2019-05-28+623,196→ 1,497,905 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Ordinary Shares
2019-05-28+18,485→ 18,485 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+377,732$5,288,248→ 1,875,637 total(indirect: By SV Life Sciences Fund V, L.P.) - Conversion
Series B1 Preferred Shares
2019-05-28−623,196→ 0 total(indirect: By SV Life Sciences Fund V, L.P.)→ Ordinary Shares (623,196 underlying) - Conversion
Ordinary Shares
2019-05-28+13,169→ 31,654 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+7,983$111,762→ 39,637 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.) - Conversion
Series B1 Preferred Shares
2019-05-28−13,169→ 0 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.)→ Ordinary Shares (13,169 underlying) - Conversion
Series A Preferred Shares
2019-05-28−874,709→ 0 total(indirect: By SV Life Sciences Fund V, L.P.)→ Ordinary Shares (874,709 underlying) - Conversion
Series A Preferred Shares
2019-05-28−18,485→ 0 total(indirect: By SV Life Sciences Fund V Strategic Partners. L.P.)→ Ordinary Shares (18,485 underlying)
Footnotes (3)
- [F1]Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
- [F3]These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein
Documents
Issuer
BICYCLE THERAPEUTICS plc
CIK 0001761612
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001644160
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 9:26 PM ET
- Size
- 30.1 KB